Clinical Expertise at Aspire for Wellness Together
Aspire for Wellness Together is led by Sandra Mannon, DNP, APRN , a family nurse practitioner whose healthcare career began in 1992. Her clinical background includes 20 years in critical care, followed by advanced practice nursing and functional medicine. Dr. Mannon also has extensive experience in healthcare education, including 10 years as adjunct faculty teaching senior nurse practitioner students. Her approach emphasizes individualized care, patient education, and long-term health and wellness.
You wake up after a full night in bed and still feel as if you've spent the night working. Your workouts no longer produce the same results, your interest in sex has faded, and the mental sharpness you relied on seems less dependable. At first, you may blame stress, family responsibilities, poor sleep, or getting older.
That explanation may be partly right, but it may not be complete. Hormone replacement therapy for men, usually called testosterone replacement therapy or TRT, can be appropriate for some men with confirmed testosterone deficiency and persistent related symptoms. It isn't a general energy treatment, an anti-aging shortcut, or a substitute for evaluating sleep, mood, metabolic health, medications, and lifestyle.
The useful question isn't whether testosterone is "low." It's whether symptoms, repeat laboratory testing, medical history, fertility plans, risks, and treatment goals support a supervised trial of therapy.
Table of Contents
- Recognizing the Signs of Low Testosterone
- Understanding Testosterone Deficiency and Its Causes
- Comparing Testosterone Delivery Methods
- Benefits and Risks of Hormone Replacement Therapy
- Evaluation and Ongoing Monitoring Protocols
- Fertility Considerations and Common Misconceptions
- Taking the Next Step Toward Personalized Care
Recognizing the Signs of Low Testosterone
A man in his late 40s may describe the change as gradual rather than dramatic. He still goes to work, manages family responsibilities, and appears healthy, but he no longer recovers from exercise well. He feels tired even after sleeping, has less motivation, notices reduced libido or erectile changes, and sees more abdominal fat with less lean muscle. Some men also describe a flatter mood or persistent cognitive fog.
Those symptoms deserve attention, but they don't identify testosterone deficiency by themselves. Fatigue can accompany thyroid dysfunction, depression, sleep apnea, medication effects, chronic illness, or metabolic syndrome. Erectile changes can involve vascular health, stress, relationship factors, medication, or diabetes. A clinician has to separate a hormone-related pattern from these overlapping possibilities.
Clinical perspective: Symptoms start the evaluation. They don't finish it.
Testosterone deficiency is common and measurable across adult age groups. A large NHANES-based analysis estimated overall deficiency at roughly 25.7%, with age-standardized prevalence declining from 29.3% in 2011–2012 to 22.4% in 2021–2023. Another estimate approximated the potentially relevant U.S. population at 33.1 million men, while a separate analysis found deficiency in 30.8% of its sample when defined as total testosterone below 300 ng/dL. That analysis reported 22.6% in young men, 35.8% in middle-aged men, and 34.6% in older men. These findings come from the peer-reviewed NHANES-related analysis of testosterone deficiency.
The practical takeaway is that low testosterone isn't limited to very old men, but neither does every symptom in midlife indicate hypogonadism. A structured assessment usually considers symptom duration, sexual symptoms, sleep quality, weight and metabolic health, medical conditions, medications, fertility intentions, and properly timed morning blood tests.
The rest of the decision depends on identifying why testosterone may be low, confirming the result, and weighing what treatment can realistically improve against what it can complicate.
Understanding Testosterone Deficiency and Its Causes
A man with fatigue, reduced sexual interest, or poorer recovery may have low testosterone, but the cause determines what should happen next. Primary hypogonadism starts in the testes, where production is impaired by testicular injury, infection, certain genetic conditions, or treatment-related damage. Secondary hypogonadism involves the hypothalamus or pituitary gland, which normally signal the testes to produce testosterone.
Obesity, type 2 diabetes, chronic opioid exposure, pituitary disorders, chronic illness, inadequate sleep, heavy alcohol intake, sustained stress, and some medications can contribute. These factors matter clinically because secondary hypogonadism may be partly reversible. Improving sleep, treating weight and metabolic disease, reviewing medications, or assessing a pituitary disorder can improve testosterone production without immediately committing a patient to lifelong exogenous therapy.
Obesity-related suppression deserves particular attention. A clinician may address weight, sleep, glucose control, and medication effects before deciding that replacement is appropriate. That approach can also clarify whether symptoms persist after reversible contributors are treated.
Total testosterone is only part of the picture
Laboratory results require context. Total testosterone includes testosterone circulating freely and testosterone bound to proteins. Free testosterone is the fraction available to tissues, while sex hormone-binding globulin, or SHBG, affects the balance between bound and available hormone.
A borderline total result can coexist with a clinically meaningful free testosterone result. Conversely, a low total result may need further interpretation before treatment. The AUA testosterone deficiency guideline emphasizes symptoms plus laboratory findings, with repeat morning testing rather than automatic treatment based on a borderline value.
Standardized testing can reduce diagnostic errors. In practice, collect two separate morning testosterone samples under appropriate conditions, then interpret them alongside symptoms, medications, sleep, metabolic health, examination findings, and fertility plans. If treatment is being considered, baseline hematocrit and fertility goals should be documented because testosterone therapy can raise hematocrit and suppress sperm production. Testing and follow-up should be planned around the selected formulation, since the timing of a blood draw affects how the result is interpreted.
Comparing Testosterone Delivery Methods
The delivery method shapes convenience, hormone fluctuations, exposure risk, cost, and how quickly a clinician can change the plan. No formulation is universally superior. The practical choice depends on symptom response, treatment preferences, fertility plans, comfort with administration, insurance or cost coverage, and the ability to complete scheduled monitoring.
Injectable testosterone cypionate or enanthate is familiar, flexible, and often relatively affordable. Levels can rise after administration and fall before the next dose, creating a peak-and-trough pattern that may affect mood, energy, libido, acne, or hematocrit. Serum testosterone is generally checked midway between injections for these formulations, consistent with endocrine dosing guidance. Hematocrit and symptom response matter as much as the testosterone number, particularly when symptoms fluctuate before the next injection.
Transdermal gels and creams provide relatively steady daily exposure without needles. They require consistent application, careful attention to washing instructions, and precautions to prevent transfer through skin contact with partners or children. Missed applications disrupt the routine, and some men find daily treatment burdensome. Testing is generally performed 2–8 hours after application, because the collection time affects interpretation.
Pellets, including BioTe-style pellet treatment, release testosterone over a longer interval. Placement requires a minor insertion procedure, and dose changes cannot be made quickly if exposure is too high or too low. Pellets may rarely extrude or cause local complications. They can suit someone who wants fewer administration days, but limited adjustability is a meaningful trade-off.
Nasal gels and buccal tablets are less common alternatives. They may suit men avoiding injections or skin transfer, although administration frequency, local tolerability, absorption, and access can reduce practicality. Product-specific instructions determine the appropriate testing schedule.
| Delivery Method | Dosing Frequency | Pharmacokinetic Profile | Key Monitoring Considerations | Best Suited For |
|---|---|---|---|---|
| Injectable cypionate or enanthate | Scheduled injections, individualized by clinician | Peaks and troughs may occur | Test midway between injections; follow hematocrit and symptom response | Men who value flexibility, familiarity, and dose adjustability |
| Transdermal gel or cream | Daily application | Relatively steady exposure with consistent use | Gel testing is generally performed 2–8 hours after application; assess transfer precautions | Men who prefer needle-free daily treatment |
| Pellets | Intervals commonly planned around the implant cycle | Longer-acting release | Pellets are checked at the end of the dosing interval; dose changes aren't immediate | Men prioritizing convenience and fewer administration days |
| Nasal gel | Repeated nasal administration | Shorter-acting exposure pattern | Follow product-specific timing and assess nasal tolerability | Men seeking a noninjection option with no skin transfer |
| Buccal tablet | Repeated placement in the mouth | Mucosal absorption | Assess oral tolerability and test according to the prescribed product | Men able to maintain a consistent buccal routine |
Before treatment, clarify how the chosen formulation affects fertility planning, hematocrit follow-up, and the timing of blood tests. Those details determine whether a convenient option remains clinically manageable.
Monthly costs vary substantially by formulation, pharmacy, coverage, clinical services, and whether insertion or follow-up is bundled. A responsible clinic should explain the full cost structure before treatment rather than present the medication price as the entire financial commitment.
Benefits and Risks of Hormone Replacement Therapy
TRT works best when the problem is testosterone deficiency and the treatment target is clinically meaningful. Men may experience improvements in sexual symptoms, lean body mass, bone mineral density, or aspects of mood and well-being. The response isn't uniform, and improvement in one domain doesn't guarantee improvement in another.
TRT doesn't reliably solve every complaint associated with midlife. Fatigue caused by sleep apnea, depression, untreated thyroid disease, medication effects, inadequate nutrition, or overtraining may persist if those contributors remain unaddressed. Testosterone also shouldn't be used as a shortcut for weight management when the primary problem is diet, inactivity, metabolic disease, or another condition.
Cardiovascular and prostate questions require nuance
The cardiovascular debate has become more precise. Current meta-analytic evidence suggests no overall increase in major adverse cardiovascular events, myocardial infarction, stroke, cardiovascular mortality, or all-cause mortality compared with placebo in hypogonadal men. A newer 2025 meta-analysis found a signal for increased cardiac arrhythmias in men aged 40 and older receiving TRT, despite no excess in myocardial infarction or stroke. The evidence is summarized in this recent cardiovascular meta-analysis.
More recent evidence is also trending toward neutrality for major cardiovascular and prostate outcomes. A 2026 meta-analysis of 41 randomized trials found no statistically significant increase in major adverse cardiovascular events or prostate cancer endpoints, while a 2025 review of the TRAVERSE trial reported similar MACE rates with testosterone versus placebo, 7.0% versus 7.3%, and no increased prostate cancer or benign prostatic hyperplasia signal, as discussed in the peer-reviewed review of these findings.
That doesn't make screening optional. TRT can increase red blood cell concentration, and erythrocytosis is the most common dose-related adverse effect identified in recent reviews. Acne, injection-site reactions, fluid changes, worsening urinary symptoms, and possible sleep apnea aggravation also require attention.
The AUA recommends baseline hemoglobin and hematocrit assessment, considering withholding treatment if hematocrit exceeds 50% until the cause is investigated, and intervening if it reaches 54% during treatment. The AUA guideline document provides the hematocrit safety framework. Prostate monitoring should follow appropriate screening guidance, with PSA evaluation and clinical assessment based on age, risk, symptoms, and treatment context.
Realistic expectation: TRT should restore an appropriate physiologic range and improve relevant symptoms. It shouldn't be sold as a universal solution for aging, athletic performance, or unexplained fatigue.
Evaluation and Ongoing Monitoring Protocols
A man may report low energy, reduced sexual interest, or poorer recovery, but those symptoms do not establish testosterone deficiency by themselves. Before prescribing, the clinician reviews symptom patterns, medical history, medications, sleep, alcohol use, weight, metabolic health, fertility plans, cardiovascular risk, prostate history, and prior laboratory results.
Diagnosis generally requires two separate morning testosterone tests. If results are borderline or do not match the clinical picture, free testosterone and SHBG can clarify interpretation. Depending on the history, baseline testing may include CBC, CMP, lipid profile, PSA, LH, FSH, estradiol, and SHBG.
A practical monitoring sequence
Follow-up must match the formulation and the patient's risks. Serum testosterone is generally checked 3–6 months after initiation, with dose adjustment toward the mid-normal range. Earlier review is appropriate if symptoms change, injections or applications are missed, or adverse effects develop.
| Timepoint | Labs Ordered | Key Clinical Actions |
|---|---|---|
| Before treatment | Morning testosterone testing, CBC with hemoglobin and hematocrit, and targeted tests such as PSA, LH, FSH, estradiol, SHBG, CMP, or lipids | Confirm candidacy, identify contraindications, discuss fertility, and establish baseline safety data |
| Early follow-up | Symptom review, administration review, blood pressure, and adverse-effect assessment | Check adherence, tolerability, and whether the delivery method fits daily life |
| 3–6 months | Serum testosterone timed to the formulation, CBC and hematocrit, with PSA or other tests when indicated | Adjust dose toward the mid-normal range and address erythrocytosis, persistent symptoms, or excessive exposure |
| Annual maintenance | Testosterone, CBC and hematocrit, prostate monitoring when appropriate, and targeted metabolic or safety tests | Continue, modify, switch, or discontinue treatment based on response and risk |
Blood-test timing can change the interpretation substantially. Injectable enanthate or cypionate is checked midway between injections. Gels are checked 2–8 hours after application, patches 3–12 hours after application, pellets near the end of the dosing interval, and oral undecanoate 3–5 hours after a fat-containing meal, according to the expert formulation-specific recommendations.
Hematocrit deserves active follow-up. If it rises, the clinician may lower the dose, change the formulation, investigate hypoxia or sleep apnea, or consider therapeutic phlebotomy when appropriate. Estradiol should be interpreted alongside symptoms and examination findings rather than suppressed automatically. Aromatase inhibitors are not routine treatment for every man receiving TRT and may create additional problems.
Endocrinology or urology input can help when pituitary disease, major laboratory abnormalities, prostate findings, infertility, or complicated cardiovascular risk is present. Broader wellness assessment may also be considered, including Aspire for Wellness Together's peptide therapy services when clinically relevant and evaluated separately from testosterone treatment.
Fertility Considerations and Common Misconceptions
The most important overlooked issue for many younger men is fertility. Exogenous testosterone signals the brain that adequate androgen is already available. The hypothalamus and pituitary reduce their reproductive signaling, intratesticular testosterone falls, and sperm production can decline substantially. Some men develop very low sperm counts or no detectable sperm, and recovery after stopping therapy isn't always immediate or predictable.
The Endocrine Society recommends against starting testosterone in men planning fertility in the near term. Its clinical practice guideline for testosterone therapy also identifies important safety screens, including prostate or breast cancer, a prostate nodule or induration, PSA above 3 ng/mL without urologic evaluation, hematocrit above 50%, untreated obstructive sleep apnea, severe lower urinary tract symptoms, and class III or IV heart failure.
Fertility-preserving paths
A man who wants symptom relief now and children later needs a different conversation from a man who has completed his family. Clinicians may consider options such as hCG monotherapy, clomiphene citrate, or combination protocols designed to support endogenous signaling. These approaches require specialist assessment and aren't interchangeable with standard TRT.
TRT also isn't identical to anabolic steroid use for bodybuilding. Medical therapy aims to correct documented deficiency within a physiologic target range, while nonmedical anabolic use may involve different substances, doses, goals, and risk patterns. That distinction doesn't remove the need for monitoring.
Another misconception is that low testosterone is always “just aging.” Age-related change exists, but persistent symptoms with confirmed biochemical deficiency may represent a treatable clinical disorder. Conversely, a low or borderline result without compatible symptoms shouldn't automatically lead to treatment.
Before fertility is relevant: Discuss sperm preservation and reproductive goals before the first prescription, not after a semen analysis changes.
Patients should also understand that stopping TRT can be difficult because the body's reproductive axis needs time to recover, and some men may require a structured discontinuation plan. For men with sexual symptoms, a broader evaluation is available through Aspire for Wellness Together's sexual rejuvenation services, but fertility intentions still need to guide the hormone discussion from the beginning.
Taking the Next Step Toward Personalized Care
Hormone replacement therapy for men is a clinical decision, not a standardized package. The strongest process combines accurate diagnosis, investigation of contributing conditions, formulation selection that fits the patient's life, and ongoing review of symptoms and safety markers.
A responsible consultation should address:
- Diagnosis: Symptoms should align with repeat, properly timed laboratory findings.
- Candidacy: Fertility plans, prostate health, sleep apnea, hematocrit, cardiovascular risk, and medications need review.
- Delivery method: Injections, topical therapy, pellets, and less common options each involve practical trade-offs.
- Follow-up: Testing must be timed to the formulation, and dose changes should reflect both laboratory results and how the patient feels.
- Broader health: Sleep, exercise, nutrition, metabolic health, mood, and sexual health can influence the same symptoms patients attribute to testosterone.
Before an appointment, document symptom changes, sleep patterns, libido and erectile concerns, medications, prior lab results, fertility goals, and questions about cost and follow-up. Aspire's discussion of hormone replacement therapy cost can help you prepare for the financial part of that conversation.
If you're in Bradenton, Florida, or nearby Gulf Coast communities such as Sarasota or Lakewood Ranch, schedule an evaluation with a qualified hormone specialist who will treat you, not just your number, and who views TRT as one tool within your metabolic, cardiovascular, sexual, and psychological health plan.
Aspire for Wellness Together offers individualized male hormone therapy, including testosterone treatment options such as injections, creams, and pellet-based care, following an evaluation of your symptoms, history, laboratory findings, risks, and goals. Visit Aspire for Wellness Together to request a consultation and discuss a monitored plan in Bradenton, Florida.
